Quest Diagnostics Incorporated (DGX)
Stock Price Chart
Key Info
| Market Cap | 16.35B |
| Revenue (ttm) | 7.53B |
| Net Income (ttm) | 752.00M |
| Shares Out | 134.30M |
| EPS (ttm) | 5.52 |
| PE Ratio | 22.06 |
| Forward PE | 18.02 |
| Dividend | $2.24 |
| Dividend Yield | 1.84% |
Stock Quote
| Trading Day | Aug 13, 2020 |
| Last Price | $121.75 |
| Previous Close | $121.15 |
| Change ($) | 0.60 |
| Change (%) | 0.50% |
| Day's Open | 120.74 |
| Day's Range | 119.80 - 121.77 |
| Day's Volume | 650,378 |
| 52-Week Range | 73.02 - 131.81 |
More Stats
| Market Cap | 16.35B |
| Enterprise Value | 20.50B |
| Earnings Date (est) | Oct 27, 2020 |
| Ex-Dividend Date | Jul 7, 2020 |
| Shares Outstanding | 134.30M |
| Float | 133.53M |
| EPS (basic) | 5.59 |
| EPS (diluted) | 5.52 |
| FCF / Share | 6.77 |
| Dividend | $2.24 |
| Dividend Yield | 1.84% |
| Earnings Yield | 4.53% |
| FCF Yield | 5.55% |
| Payout Ratio | n/a |
| Shares Short | 2.76M |
| Short Ratio | 2.00 |
| Short % of Float | 2.33% |
| Beta | 1.38 |
| PE Ratio | 22.06 |
| Forward PE | 18.02 |
| P/FCF Ratio | 18.03 |
| PS Ratio | 2.17 |
| PB Ratio | 2.87 |
| Revenue | 7.53B |
| Operating Income | 1.13B |
| Net Income | 752.00M |
| Free Cash Flow | 907.00M |
| Net Cash | -4.15B |
| Net Cash / Share | -30.89 |
| Gross Margin | 36.17% |
| Operating Margin | 15.06% |
| Profit Margin | 10.00% |
| FCF Margin | 12.04% |
| ROA | 5.61% |
| ROE | 13.69% |
| ROIC | n/a |
Analyst Summary
Analyst Consensus: Buy
Financial Performance
Financial Overview
| Year | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | 2010 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 7,726 | 7,531 | 7,402 | 7,214 | 7,493 | 7,435 | 7,146 | 7,383 | 7,392 | 7,260 |
| Revenue Growth | 2.59% | 1.74% | 2.61% | -3.72% | 0.78% | 4.04% | -3.21% | -0.12% | 1.82% | - |
| Gross Profit | 2,689 | 2,605 | 2,683 | 2,598 | 2,836 | 2,798 | 2,820 | 3,018 | 3,029 | 2,985 |
| Operating Income | 1,231 | 1,101 | 1,165 | 1,277 | 1,399 | 983 | 1,001 | 1,201 | 987 | 1,284 |
| Net Income | 858 | 736 | 772 | 645 | 709 | 556 | 849 | 556 | 471 | 721 |
| Shares Outstanding | 135 | 136 | 136 | 139 | 143 | 145 | 145 | 159 | 158 | 170 |
| Earnings Per Share | 6.28 | 5.29 | 5.50 | 4.51 | 4.87 | 3.81 | 5.54 | 3.46 | 2.92 | 4.05 |
| EPS Growth | 18.71% | -3.82% | 21.95% | -7.39% | 27.82% | -31.23% | 60.12% | 18.49% | -27.9% | - |
| Dividend Per Share | 2.12 | 1.95 | 1.80 | 1.58 | 1.47 | 1.29 | 1.20 | 0.68 | 0.40 | 0.40 |
| Dividend Growth | 8.72% | 8.33% | 13.92% | 7.48% | 13.95% | 7.5% | 76.47% | 70% | 0% | - |
| Operating Cash Flow | 1,243 | 1,200 | 1,175 | 1,116 | 821 | 944 | 652 | 1,187 | 895 | 1,118 |
| Capital Expenditures | -309 | -381 | -251 | -293 | -263 | -308 | -231 | -182 | -161 | -205 |
| Free Cash Flow | 934 | 819 | 924 | 823 | 558 | 636 | 421 | 1,005 | 734 | 913 |
| Cash & Equivalents | 1,192 | 135 | 137 | 359 | 133 | 192 | 187 | 296 | 165 | 449 |
| Total Debt | 5,328 | 3,893 | 3,784 | 3,734 | 3,651 | 3,742 | 3,332 | 3,364 | 4,025 | 2,990 |
| Net Cash / Debt | -4,136 | -3,758 | -3,647 | -3,375 | -3,518 | -3,550 | -3,145 | -3,068 | -3,860 | -2,541 |
| Assets | 12,843 | 11,003 | 10,503 | 10,100 | 9,962 | 9,857 | 8,948 | 9,284 | 9,313 | 8,528 |
| Liabilities | 7,156 | 5,736 | 5,548 | 5,440 | 5,249 | 5,527 | 4,975 | 5,098 | 5,598 | 4,474 |
| Book Value | 5,641 | 5,216 | 4,921 | 4,628 | 4,684 | 4,301 | 3,948 | 4,163 | 3,693 | 4,033 |
Company Profile
Company Details
| Full Name | Quest Diagnostics Incorporated |
| Country | United States |
| Employees | 47,000 |
| CEO | Stephen H. Rusckowski |
Stock Information
| Ticker Symbol | DGX |
| Stock Exchange | New York Stock Exchange |
| Sector | Healthcare |
| Industry | Diagnostics & Research |
| Unique Identifier | NYSE: DGX |
| IPO Date | December 17, 1996 |
Description
Quest Diagnostics Incorporated provides diagnostic testing, information, and services in the United States and internationally. The company develops and delivers diagnostic information services, such as routine testing, non-routine and advanced clinical testing, anatomic pathology testing, and other diagnostic information services. It offers diagnostic information services primarily under the Quest Diagnostics brand, as well as under the AmeriPath, Dermpath Diagnostics, Athena Diagnostics, ExamOne, and Quanum brands to patients, clinicians, hospitals, integrated delivery networks, health plans, employers, and accountable care organizations through a network of laboratories, patient service centers, phlebotomists in physician offices, call centers and mobile paramedics, nurses, and other health and wellness professionals. The company also offers risk assessment services for the life insurance industry; and healthcare organizations and clinicians robust information technology solutions. Quest Diagnostics Incorporated has a strategic collaboration with hc1; and strategic relationship with Clinical Genomics Pty Ltd. The company was founded in 1967 and is headquartered in Secaucus, New Jersey.